Lazard Asset Management
OVID icon

Lazard Asset Management’s Ovid Therapeutics OVID Stock Holding History

Lazard Asset Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18,913
Closed -$63K – 2413
2021
Q3 		$63K Buy
18,913
+4,757
+34% +$17.3K ﹤0.01% 1574
2021
Q2 		$55K Buy
+14,156
New +$55.9K ﹤0.01% 1559

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lazard Asset Management's OVID Position: Q4 2021 in Review

Lazard Asset Management sold out of Ovid Therapeutics (OVID) in Q4 2021, closing a stake of 18,913 shares — an estimated $63K sold.

Lazard Asset Management first reported a position in OVID in Q2 2021 and held it in 2 quarters. The position peaked at $63K in Q3 2021. 67 funds tracked by Wall St. Rank hold OVID as of Q4 2021.

  • Lazard Asset Management reported no remaining Ovid Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Lazard Asset Management sold 18,913 Ovid Therapeutics shares in Q4 2021, an estimated $63K.
  • Lazard Asset Management first reported a position in Ovid Therapeutics in Q2 2021 and held it in 2 quarters.
  • Lazard Asset Management's Ovid Therapeutics position peaked at $63K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2021.

Based on Lazard Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.